Literature DB >> 9580803

Panniculitis in association with apomorphine infusion.

K M Acland1, A Churchyard, C L Fletcher, K Turner, A Lees, P M Dowd.   

Abstract

This study was undertaken to ascertain the histopathology and aetiology of cutaneous nodules observed in Parkinson's patients treated with continuous subcutaneous apomorphine. Ten patients were recruited, answered questionnaires, and underwent skin biopsies and full blood count, and nine were patch tested to apomorphine and its preservative. Six had serum IgE levels measured. A florid panniculitis was seen in all biopsies; five were predominantly eosinophilic, three lymphocytic and two neutrophilic; in seven cases the panniculitis was mixed and in three it was septal. Patch testing was universally negative and the IgE levels were normal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580803     DOI: 10.1046/j.1365-2133.1998.02128.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

2.  Apomorphine in idiopathic restless legs syndrome: an exploratory study.

Authors:  G G Tribl; T Sycha; N Kotzailias; J Zeitlhofer; E Auff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

Review 3.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

4.  ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability.

Authors:  Yuval Ramot; Abraham Nyska; Liat Adar; Cecile Durlach; Danny Fishelovitch; Giuseppe Sacco; Rosa Anna Manno; Sheila Oren; Itay Perlstein; Oron Yacobi-Zeevi
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

Review 5.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 6.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

7.  Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.

Authors:  Peter Hagell; Arja Höglund; Carina Hellqvist; Eva-Lena Johansson; Berit Löwed; Anne-Christine Sjöström; Carina Karlberg; Margareth Lundgren; Nil Dizdar; Anders Johansson; Thomas Willows; Johan Rådberg; Filip Bergquist
Journal:  J Neurol       Date:  2020-07-01       Impact factor: 4.849

Review 8.  The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues.

Authors:  Matej Skorvanek; Kailash P Bhatia
Journal:  Mov Disord Clin Pract       Date:  2016-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.